CLINICAL TRIALS PROFILE FOR ELIXOPHYLLIN
✉ Email this page to a colleague
All Clinical Trials for ELIXOPHYLLIN
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT04551170 ↗ | Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old | Recruiting | Vanderbilt University Medical Center | Phase 2 | 2020-07-13 | Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ELIXOPHYLLIN
Condition Name
Clinical Trial Locations for ELIXOPHYLLIN
Trials by Country
Clinical Trial Progress for ELIXOPHYLLIN
Clinical Trial Phase
Clinical Trial Sponsors for ELIXOPHYLLIN
Sponsor Name